Hims & Hers debates ‘unresolved’ after earnings, says Morgan Stanley
Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.
Hims & Hers Stock Tumbles Despite Beating Expectations
Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering ...
SchaeffersResearch.com4d
Hims and Hers Stock Drops Weight as Earnings Loom
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Morgan Stanley downgrades Hims & Hers on valuation concerns
Morgan Stanley downgraded Hims Hers Health Inc (NYSE:HIMS) to "Equal-weight" from "Overweight" as the stock’s recent strong performance leaves limited near-term upside, despite continued business ...
Piper Sandler Keeps Their Hold Rating on Hims & Hers Health (HIMS)
In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), ...
Hims & Hers Health (NYSE:HIMS) Downgraded by Morgan Stanley to Equal Weight
Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...
Market Whales and Their Recent Bets on HIMS Options
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...
Hims & Hers Shares Sink Despite Upbeat Earnings, Outlook
Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...
Hims & Hers Health (NYSE:HIMS) Sees Large Volume Increase After Analyst Upgrade
Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) saw unusually-high trading volume on Friday after Bank of America raised their price target on the stock from $18.00 to $21.00. Bank of ...